EDEN PRAIRIE, Minn.,
Jan. 18, 2022 /PRNewswire/
-- NeuroOne Medical Technologies Corporation (NASDAQ: NMTC)
("NeuroOne" or the "Company"), a medical technology company focused
on improving surgical care options and outcomes for patients
suffering from neurological disorders today announces the
appointment of Chad Wilhelmy, as
Vice President of Quality Control and Regulatory Affairs. Mr.
Wilhelmy joins NeuroOne from HLT Medical, a subsidiary of the
Bracco Group, where he was the Vice President Quality
Assurance.
Dave Rosa, CEO of NeuroOne
Medical Technologies Corporation says, "Chad's appointment further
strengthens our executive leadership team and deepens our
capabilities as we build the platform for future growth and
expansion. We believe his vast experience in the medical device
space will help us build the essential regulatory and quality
foundation needed to realize our company's ambitious goals."
Chad Wilhelmy, newly appointed
Vice President of Quality Control and Regulatory Affairs,
commented, "I'm excited to join such a talented and innovative
team. The applications and market opportunities for NeuroOne's
electrode technology are tremendous."
Chad Wilhelmy joins NeuroOne with
20 years of medical device experience developing, implementing, and
leading quality management systems. Prior to joining
NeuroOne, he held top leadership roles at HLT Medical as the Vice
President of Quality and at Sunshine Heart as the Senior Director
of Quality. He has driven quality strategies from early-stage
development to commercial distribution with both the FDA and
Notified Body. Chad earned a Bachelor of Science degree from the
University of Wisconsin - Stout in
Engineering Technology with an emphasis in Quality.
As a material inducement to entering into employment
with NeuroOne, Mr. Wilhelmy, who was not previously an
employee or director of NeuroOne, received an option to
purchase 50,000 shares of the Company's common stock under the
NeuroOne Medical Technologies Corporation 2021 Inducement Plan (the
"Inducement Plan"). The equity award under the Inducement Plan was
approved by the Company's Compensation Committee, which is composed
entirely of independent directors, in accordance with Nasdaq
Listing Rule 5635(c)(4), which also requires a public announcement
of equity awards that are not made under a stockholder approved
equity plan.
The option award has an exercise price of $1.95 per
share, the closing price of NeuroOne's common stock on January
14, 2022, the date of the grant. The option has a ten-year term and
vests as to 25% on January 1, 2023,
with the remaining shares vesting in equal monthly installments on
the last day of each month over the next thirty-six (36) months,
provided Mr. Wilhelmy's employment is continuing on each such
date.
About NeuroOne
NeuroOne Medical Technologies Corporation is a developmental
stage company committed to providing minimally invasive and
hi-definition solutions for EEG recording, brain stimulation and
ablation solutions for patients suffering from epilepsy,
Parkinson's disease, dystonia, essential tremors, chronic pain due
to failed back surgeries and other related neurological disorders
that may improve patient outcomes and reduce procedural costs. For
more information,
visit https://www.n1mtc.com .
Forward Looking Statements
This press release may include forward-looking statements within
the meaning of Section 27A of the Securities Act of 1933, as
amended, and Section 21E of the Securities Exchange Act of 1934, as
amended. Except for statements of historical fact, any information
contained in this presentation may be a forward–looking statement
that reflects the Company's current views about future events and
are subject to known and unknown risks, uncertainties and other
factors that may cause our actual results, levels of activity,
performance or achievements to be materially different from the
information expressed or implied by these forward-looking
statements. In some cases, you can identify forward–looking
statements by the words or phrases "may," "might," "will," "could,"
"would," "should," "expect," "intend," "plan," "objective,"
"anticipate," "believe," "estimate," "predict," "project,"
"potential," "target," "seek," "contemplate," "continue, "focused
on," "committed to" and "ongoing," or the negative of these terms,
or other comparable terminology intended to identify statements
about the future. Although the Company believes that we have a
reasonable basis for each forward-looking statement, we caution you
that these statements are based on a combination of facts and
factors currently known by us and our expectations of the future,
about which we cannot be certain. Our actual future results may be
materially different from what we expect due to factors largely
outside our control, including risks and uncertainties related to
market and other conditions, the impact of general economic,
industry or political conditions in the United States or
internationally and those described under the heading "Risk
Factors" in our filings with the Securities and Exchange
Commission. These forward–looking statements speak only as of the
date of this press release and the Company undertakes no obligation
to revise or update any forward–looking statements for any reason,
even if new information becomes available in the future.
View original
content:https://www.prnewswire.com/news-releases/neuroone-appoints-chad-wilhelmy-as-vice-president-of-quality-control-and-regulatory-affairs-301461804.html
SOURCE NeuroOne Medical Technologies Corporation